UnitedHealth Group (NYSE:UNH) Stock Gets Price Target Bump from Piper Sandler

UnitedHealth Group (NYSE:UNH) had its target price upped by equities research analysts at Piper Sandler from $502.00 to $504.00 in a research report issued on Wednesday, Benzinga reports. The firm currently has an “overweight” rating on the healthcare conglomerate’s stock. Piper Sandler’s price objective would indicate a potential upside of 29.84% from the stock’s previous close.

Several other equities research analysts have also recently weighed in on UNH. KeyCorp reaffirmed an “overweight” rating on shares of UnitedHealth Group in a research report on Wednesday. Mizuho boosted their target price on shares of UnitedHealth Group from $470.00 to $493.00 and gave the company an “outperform” rating in a research report on Monday, July 20th. Deutsche Bank Aktiengesellschaft increased their price target on shares of UnitedHealth Group from $370.00 to $467.00 and gave the stock a “hold” rating in a research report on Friday, July 17th. UBS Group restated an “outperform” rating on shares of UnitedHealth Group in a research note on Tuesday. Finally, Cantor Fitzgerald lifted their price target on UnitedHealth Group from $440.00 to $495.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Twenty investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $461.83.

UnitedHealth Group Price Performance

NYSE UNH traded up $10.41 during midday trading on Wednesday, hitting $388.17. The company had a trading volume of 3,802,300 shares, compared to its average volume of 7,359,070. The firm has a 50-day moving average price of $387.44 and a 200-day moving average price of $382.57. The company has a market capitalization of $348.42 billion, a PE ratio of 24.96, a P/E/G ratio of 1.42 and a beta of 0.60. The company has a current ratio of 0.78, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. UnitedHealth Group has a twelve month low of $255.96 and a twelve month high of $461.62.

UnitedHealth Group (NYSE:UNH) last released its earnings results on Tuesday, October 13th. The healthcare conglomerate reported $4.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.14 by $0.55. UnitedHealth Group had a return on equity of 16.53% and a net margin of 3.14%. The company had revenue of $112.70 billion for the quarter, compared to analyst estimates of $111.31 billion. During the same period in the prior year, the firm posted $2.59 EPS. UnitedHealth Group’s quarterly revenue was down .4% on a year-over-year basis. UnitedHealth Group has set its FY 2026 guidance at 20.500- EPS. As a group, analysts anticipate that UnitedHealth Group will post 19.85 earnings per share for the current fiscal year.

Insider Activity at UnitedHealth Group

In related news, CEO Patrick Conway sold 1,169 shares of the firm’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $390.00, for a total transaction of $455,910.00. Following the sale, the chief executive officer owned 15,328 shares of the company’s stock, valued at $5,977,920. This trade represents a 7.09% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.19% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. lifted its holdings in UnitedHealth Group by 4.6% during the 2nd quarter. BlackRock Inc. now owns 76,863,061 shares of the healthcare conglomerate’s stock worth $31,946,594,000 after buying an additional 3,395,530 shares during the period. State Street Corp increased its stake in shares of UnitedHealth Group by 0.7% in the second quarter. State Street Corp now owns 45,633,267 shares of the healthcare conglomerate’s stock valued at $18,966,555,000 after buying an additional 301,081 shares during the period. Bank of New York Mellon Corp increased its stake in shares of UnitedHealth Group by 6.1% in the second quarter. Bank of New York Mellon Corp now owns 10,704,994 shares of the healthcare conglomerate’s stock valued at $4,449,317,000 after buying an additional 616,723 shares during the period. Wellington Management Group LLP raised its position in shares of UnitedHealth Group by 5.8% during the second quarter. Wellington Management Group LLP now owns 10,675,175 shares of the healthcare conglomerate’s stock worth $4,436,923,000 after acquiring an additional 583,536 shares during the last quarter. Finally, Corient Private Wealth LP lifted its stake in shares of UnitedHealth Group by 1,443.7% in the second quarter. Corient Private Wealth LP now owns 8,447,224 shares of the healthcare conglomerate’s stock worth $3,510,920,000 after acquiring an additional 7,900,011 shares during the period. Institutional investors and hedge funds own 87.86% of the company’s stock.

UnitedHealth Group News Summary

Here are the key news stories impacting UnitedHealth Group this week:

• Positive Sentiment: Third-quarter results exceeded expectations. Adjusted EPS was $4.69 versus the $4.14 consensus, while revenue of $112.7 billion topped estimates of $111.3 billion. Operating earnings increased 52% to $6.6 billion, helped by lower medical costs and improved execution. UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costs
• Positive Sentiment: Management raised 2026 guidance. UnitedHealth now expects adjusted EPS of at least $20.50, above the roughly $19.86 analyst consensus, reinforcing confidence in recovering margins. UnitedHealth Group Reports Third Quarter 2026 Results
• Positive Sentiment: The 2027 outlook is improving. Executives highlighted a long-term earnings-growth target of 13% to 16%, potential margin recovery in Medicaid after 2026, and continued benefits from artificial intelligence. AI tools reportedly reduced clinical-review times by 33%, while the medical care ratio improved to 88.4%. UNH Q3 Earnings Call Highlights 2027 Growth and Margin Recovery
• Neutral Sentiment: Analyst opinion remains mixed. Mizuho maintained UnitedHealth as a top healthcare pick, while Barclays trimmed its target to $440 but kept an overweight rating. Baird cut its target to $427 and assigned a neutral rating. UnitedHealth Stock Forecast: TD Cowen Stays Cautious Even as Mizuho Names UNH a Top Pick
• Negative Sentiment: Risks remain around profitability. Commercial medical costs and Medicaid pressures continue to challenge margins, and some analysts lowered forecasts following the results. Revenue was essentially flat year over year, while the company’s Medicare business changes and membership reductions remain concerns for investors. UnitedHealth Analysts Slash Their Forecasts Following Q3 Results

About UnitedHealth Group

UnitedHealth Group Incorporated (NYSE: UNH) is a diversified health care and well-being company serving individuals, employers, health care providers and government programs. Its operations are organized primarily through UnitedHealthcare and Optum.

UnitedHealthcare provides health benefit plans and services, including employer-sponsored coverage, individual and family plans, Medicare and Medicaid offerings, and other government-supported programs. Its services include health insurance administration, pharmacy benefits and care management.

Optum provides health care services, technology and data solutions, pharmacy services, and analytics to health plans, employers, government agencies, health care providers and consumers.